Targeted Oncology1h
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
Targeted Oncology19h
Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease
In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their ...
Targeted Oncology4h
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Targeted Oncology3h
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly ...
Targeted Oncology6h
Adverse Event Management: Amivantamab
Hatim Husain, MD, discusses how the implementation of proactive prophylaxis strategies for patients taking amivantamab, ...
Targeted Oncology23h
The Lasting Impact of the CROSS Trial on GEJ Cancer Care
Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction ...
Targeted Oncology22h
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...